Acorda Therapeutics Inc. plans to appeal the U.S. District Court of Delaware ruling that invalidated four U.S. patents related to its multiple sclerosis drug AMPYRA.

The court, meanwhile, upheld a patent related to the drug, which is set to expire in July 2018.

The U.S. Patent and Trademark Office had previously upheld these four patents which were challenged via the inter partes review process.